Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Share (Tables)

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended
	March 31,
	2020		2019
EPS Numerator:
Net income (loss)	$	21,243	$	(17,598)
EPS Denominator—Basic:
Weighted-average common shares outstanding		168,469		167,173
EPS Denominator—Diluted:
Weighted-average common shares outstanding		168,469		167,173
Dilutive effect of stock options, shares under ESPP and warrant		99		—
Weighted-average shares outstanding and common stock equivalents		168,568		167,173
Net income (loss) per common share:
Basic	$	0.13	$	(0.11)
Diluted	$	0.13	$	(0.11)

Schedule of antidilutive securities

We had securities which could potentially dilute basic earnings per share, but were excluded from the computation of diluted earnings (loss) per share for all periods presented, as their effect would have been antidilutive. These securities consist of the following (in thousands):


	Three Months Ended
	March 31,
	2020		2019
Outstanding stock options		23,206		25,126
Purchase Plan		—		130
Total		23,206		25,256